Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Renae Chavira"'
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2675-2686 (2023)
Abstract Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and
Externí odkaz:
https://doaj.org/article/92898601b9704065a9ccb921465d6d65
Autor:
Emma Barrett, Gina Fernetich, Tara Baetz, Renae Chavira, Tessa McSpadden, Kari Guthrie, Stephen Chia, Rashmi Krishna Murthy, Stacy L. Moulder, Virginia F. Borges
Publikováno v:
Clinical Cancer Research. 23:3529-3536
Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD, pharmacokinetics (PK) and antitumor activity of ONT-380 in HER2-positive advanced solid tumors, with an expansion cohort of patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::402550103083b974e694f8f234784f1f
https://doi.org/10.1158/1078-0432.ccr-16-1496
https://doi.org/10.1158/1078-0432.ccr-16-1496
Autor:
Benjamin R. Tan, Colin D. Weekes, Emma Barrett, Milind Javle, Renae Chavira, Tanios Bekaii-Saab, Amita Patnaik, Johanna C. Bendell, Daniel A. Laheru, Janna Christy-Bittel, Michael B. Sawyer, Gazala Khan, Richard S. Finn, Daniel H. Ahn
Publikováno v:
Investigational new drugs. 36(6)
Background The MAPK pathway plays a central role in regulation of several cellular processes, and its dysregulation is a hallmark of biliary tract cancer (BTC). Binimetinib (MEK162), a potent, selective oral MEK1/2 inhibitor, was assessed in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b02a912565d8734079944c0a1fa9c5f
https://pubmed.ncbi.nlm.nih.gov/29785570
https://pubmed.ncbi.nlm.nih.gov/29785570
Autor:
Suzanne F. Jones, Kyriakos P. Papadopoulos, Mark M. Zalupski, Johanna C. Bendell, Janna L. Christy-Bittel, Emma Barrett, Gazala Khan, Richard S. Finn, Jeffrey R. Infante, Anthony W. Tolcher, Amita Patnaik, Tanios Bekaii-Saab, Milind Javle, Daniel A. Laheru, Colin D. Weekes, Renae Chavira, Benjamin R. Tan, Zev A. Wainberg
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 116, iss 5
British journal of cancer, vol 116, iss 5
Background: Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined the maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and preliminary anti-tumour activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecfedf8a5e291a8e8688a644fad19576
https://pubmed.ncbi.nlm.nih.gov/28152546
https://pubmed.ncbi.nlm.nih.gov/28152546
Autor:
D. Scott McMeekin, Michael S. Gordon, Emma Barrett, Rachel N. Grisham, Wael A. Harb, Renae Chavira, Kristin McKinley, Janna Christy-Bittel, Kathleen N. Moore, Carol Aghajanian, Lisa Anderson
Publikováno v:
Journal of Clinical Oncology. 33:5516-5516
5516 Background: Ovarian cancer is associated with key genetic alterations, including those that lead to activation of the RAS/RAF/MEK/ERK pathway. Binimetinib (BINI) is a potent, selective, allost...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f58e0d682b13334fb23d51f64cf4de8a
https://doi.org/10.1200/jco.2015.33.15_suppl.5516
https://doi.org/10.1200/jco.2015.33.15_suppl.5516
Autor:
Gina Fernetich, Tara Baetz, Virginia F. Borges, Tessa McSpadden, Jennifer Garrus, Steven K.L Chia, Susan D'Aloisio, Bessie Sajan, Stacy L. Moulder, Emma Barrett, Kari Guthrie, Renae Chavira
Publikováno v:
Molecular Cancer Research. 11:A050-A050
Background: Overexpression of HER2 occurs in ~25% of breast cancers. Despite the treatment successes achieved to date, improved clinical outcomes remain needed, including prevention and treatment of CNS metastases. Small-molecule HER2 inhibitors may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b0d6a2d86e05194c9b40688e5ce6dd
https://doi.org/10.1158/1557-3125.advbc-a050
https://doi.org/10.1158/1557-3125.advbc-a050